SUMMARY
The immunosuppressive function of regulatory B cells has been shown in several murine models of chronic inflammation, including collagen-induced arthritis, inflammatory bowel disease, and experimental autoimmune encephalomyelitis. Despite interest in these cells, their relevance to the maintenance of peripheral tolerance in humans remains elusive. Here, we demonstrate that human CD19 + CD24
hi CD38 hi B cells possessed regulatory capacity. After CD40 stimulation, CD19 + CD24 hi CD38 hi B cells suppressed the differentiation of T helper 1 cells, partially via the provision of interleukin-10 (IL-10), but not transforming growth factor-b (TGF-b), and their suppressive capacity was reversed by the addition of CD80 and CD86 mAbs. In addition, CD19 + CD24 hi CD38 hi SLE B cells isolated from the peripheral blood of systemic lupus erythematosus (SLE) patients were refractory to further CD40 stimulation, produced less IL-10, and lacked the suppressive capacity of their healthy counterparts. Altered cellular function within this compartment may impact effector immune responses in SLE and other autoimmune disorders.
INTRODUCTION
Regulatory cells are important for maintenance of immunological homeostasis and self-tolerance (Hayday and Tigelaar, 2003; Mauri and Ehrenstein, 2008; Van Parijs and Abbas, 1998) . In the majority of autoimmune diseases, B cells are generally considered to be pathogenic because of their capacity to secrete autoantibodies (Shlomchik et al., 1994; Yanaba et al., 2008b) . However, it has emerged that specific subsets of B cells downregulate immune responses in mice, and their absence or loss results in exacerbated autoimmune responses (Fillatreau et al., 2002; Mauri et al., 2003; Mizoguchi et al., 1997) . Different B cell subsets have been ascribed with regulatory function, such as CD5 + B-1a cells (Carroll and Prodeus, 1998; Silverman et al., 2008) , CD19 hi CD1d hi CD5 + B cells (Matsushita et al., 2008; Yanaba et al., 2008a) , or marginal zone (MZ) B cells Lenert et al., 2005) . We recently demonstrated that interleukin-10 (IL-10) + fer of T2-MZP B cells from naive or convalescent mice prevented recipient syngeneic DBA/1 mice from developing arthritis (Evans et al., 2007) . We have also identified regulatory B (Breg) cells with a similar phenotype (T2-like) in MRL/lpr mice, which spontaneously develop lupus-like disease, and demonstrated that they can be enriched upon short-term in vitro culture with agonistic CD40 monoclonal antibody (mAb) (Blair et al., 2009 ). Functional analysis of murine Breg cells showed that this population preferentially produce IL-10, but can also release transforming growth factor-b (TGF-b), interferon-g (IFN-g), and interleukin-12 (IL-12) (Blair et al., 2009; Evans et al., 2007; Fillatreau et al., 2002; Mizoguchi et al., 2002; Sugimoto et al., 2007; Tian et al., 2001) . Detailed characterization in vitro and in vivo revealed that their suppressive capacity is mediated by the provision of IL-10 and by direct contact with CD4 + T cells (Mauri et al., 2003) (Mizoguchi et al., 2002) .
CD40 signaling is pivotal for the generation and function of Breg cells in experimental autoimmune encephalomyelitis (EAE), CIA, and lupus and inflammatory bowel disease models (Fillatreau et al., 2002; Mauri et al., 2003; Mizoguchi et al., 2000) . In CIA, stimulation of B cells with an agonistic CD40 mAb gives rise to a population of B cells with potent suppressive capacity both in vivo and in vitro (Mauri et al., 2003) . Chimeric mice reconstituted with CD40-deficient B cells, but having otherwise normal immune systems, are unable to recover from EAE because of the inability of the B cells to produce IL-10 (Fillatreau et al., 2002) . Similarly, CD40-deficient B cells are unable to protect colitis prone TCRa knockout (KO) mice from developing inflammatory colitis, unlike wild-type B cells (Mizoguchi et al., 1997) . Engagement of CD40 on human B cells leads preferentially, as in mice, to the production of IL-10 (Duddy et al., 2004) . However, in contrast to the murine studies, there is a paucity of data regarding any potential role for an equivalent regulatory B lymphocyte population either in healthy individuals or in patients with autoimmune disease (Duddy et al., 2007) (Correale et al., 2008) . In this study, we examined the functional regulatory properties of peripheral blood (PB)-derived human B cell subsets from 
CD24
hi CD38 hi B Cells from Healthy Individuals Suppress T Helper Cell Differentiation (A) PBMCs were stained with CD19, CD24, and CD38 and gated as previously shown (Carsetti et al., 2004 (Matsushita et al., 2008; Yanaba et al., 2008a (Grammer and Lipsky, 2003; Rahman and Isenberg, 2008; Suen et al., 2009 Figure 1A) . Interestingly, the majority of the CD19 + CD5 + CD1d hi B cells (71%), previously reported to be regulatory in experimental models of inflammation (Matsushita et al., 2008; Yanaba et al., 2008a) Figure 1A and Figure S1A Figures   1D and 1E ). This inhibitory effect was cell dose dependent ( Figure 1F ). CD19 + CD24 hi CD38 hi B cells were, at least under these experimental conditions, unable to suppress Th17 cell differentiation ( Figure S1B ). 3B ; cumulative results of this and additional results are shown as bar charts on the right), suggesting that, similarly to the murine experimental models of autoimmunity, additional interactions are necessary for Breg cells to achieve their full suppressive potential (Mann et al., 2007; Mizoguchi et al., 2000 (C) Supernatants from purified B cell subsets, cultured as in (A), were tested for the presence of IL-10 prior to stimulation with PMA+iono by ELISA. Data are shown as mean ± SE. Data were compared by statistical analysis with the two-tailed t test analysis (CHO-CD154 versus other groups); **p < 0.005, ***p < 0.0001. PBMCs from healthy donors were cultured for 72 hr with CHO-CD154 cells. PMA+iono were added for the last 6 hr of culture. Cells were then stained with CD19, CD24, and CD38 mAbs and intracellularly stained with IL-10 mAb or with an appropriate isotype control. plate-bound CD3 mAb in the presence of blocking antibodies to IL-10 and IL-10R, TGF-b, CD80, or CD86 or with their matching irrelevant isotype control (data not shown) (10 mg/ml of IL-10 and IL-10R mAbs; 2 mg/ml of TGFb mAb, 10 mg/ml of CD86 mAb, 10 mg/ml of CD80 mAb). PMA+iono were added for the last 6 hr of culture. Cells were surface stained for the expression of CD4 and intracellularly stained for IFN-g and TNF-a. Expression of TNF-a and IFN-g was assessed relative to isotype-matched control mAbs. Flow cytometry plots of (A) TNF-a and (B) IFN-g expression by CD4 + T cells cultured alone or in the presence T cell almost as efficiently as they were able to suppress cytokine expression by autologous healthy CD4 + T cells ( Figure 4C ). Therefore, it is unlikely that the lack of suppression by SLE CD19 + CD24 hi CD38 hi B cells observed in Figure 4A reflects intrinsic differences in effector T cell activity in SLE versus control donors. Figure 5A ) (Sims et al., 2005 PBMCs isolated from patients with SLE or healthy controls were stained with CD19, CD24, and CD38 and DAPI and gated as shown in Figure 1A . isolated from healthy donors). Consistent with this idea, we observed a profound impairment in IL-10 production after coculture with CHO-CD154 cells followed by PMA+iono stimulation ( Figures 5C and 5D ). In particular, whereas healthy CD19 + CD24 hi CD38 hi B cells responded to CD40 engagement, followed by PMA+ion stimulation, by upregulating IL-10 production, SLE CD19 + CD24 hi CD38 hi B cells were refractory to the same combination of stimuli ( Figures 5C and 5D ). In contrast to the IL-10 production by SLE B cells after CD40 engagement, the levels of IL-10 production upon CpG+PMA+ion stimulation were restored to levels nearly equivalent to those observed in healthy controls. Stimulation of rodent splenocytes or human PBMCs with CPG was previously shown to upregulate the production of IL-10 by B cells (Barr et al., 2007; Brummel and Lenert, 2005; Gantner et al., 2003 hi B cells isolated from SLE patients are unable to express IL-10 after activation via CD40, followed by PMA+iono stimulation ( Figure 5D ). We also tested whether this deficit reflected a defect in CD40 expression. CD40 was similarly expressed on B cells derived from healthy and SLE patients, indicating that the lack of IL-10 upregulation was not due simply to a decrease in CD40 expression (data not shown). Figure S6 ).
SLE

DISCUSSION
The delicate balance between pathogen-induced effector functions and endogenous tolerance-mediating mechanisms is of vital importance to the integrity of a host in the course of an immune response (Kyewski and Klein, 2006) . So far maintenance of this balance has been mainly attributed to regulatory T (Treg) cells (Belkaid and Tarbell, 2009 engagement (Masood et al., 1995; Rousset et al., 1992 int B cells, in the peripheral blood also express IL-10. Our results suggest that, in addition to IL-10 production, other soluble factors or costimulatory molecules that might be present specifically on the CD24 hi CD38 hi B cell subset could be required for suppression.
It remains to be formally proven whether the IL-10-producing B cells contained within these other B cell subsets are functionally suppressive. At present we have no means of purifying exclusively those B cells that express IL-10 in sufficient quantities to perform functional studies. It is therefore important to continue to address the existence of potential additional regulatory B cell subsets, given that they might play a role in the maintenance of the balance between tolerance and autoimmunity. Despite phenotypic and functional similarities, our studies revealed several key differences between murine and human regulatory B cells. The suppressive activity of murine Breg cells is primarily, if not exclusively, IL-10 dependent Mauri and Ehrenstein, 2008; Mizoguchi and Bhan, 2006) . In contrast, whereas neutralization of IL-10 in human B cell and T cell cocultures completely restored TNF-a production by target CD4 + T cells, IL-10 inhibition alone did not fully restore T cell IFN-g production. In addition, whereas in mice TGF-b has been shown to mediate Breg cell-suppressive activity in experimental diabetes (Tian et al., 2001) , human CD19 + CD24
hi CD38 hi B cellsuppressive capacity is not dependent on TGF-b production.
An important feature of the suppressive capacity of human CD19 + CD24
hi CD38 hi B cell is the involvement of CD80 and CD86. In a TCRa KO mouse model of intestinal inflammation, CD86 in particular has been reported to mediate the suppressive Immunity Characterization of Human Regulatory B Cells . PMA+iono were added for the last 6 hr of culture. Cells were surface stained with CD19, CD24, and CD38 mAbs and intracellularly stained for IL-10. Expression of IL-10 was assessed relative to isotype matched control mAbs. B cell subsets were gated as in (A).
effects of B cells (Mann et al., 2007; Mizoguchi et al., 2000) . Moreover, it has been shown that blockade of CD80 impairs Treg cell-suppressive capacity (Hajoui et al., 2004) . Our results suggest that CD80 and CD86 interactions between B cells and CD4 + T cells work synergistically with B cell IL-10 production to suppress CD4 + T cell cytokine production. CD28 and CTLA-4, both expressed by a variety of T cell populations, including regulatory T cells, are both ligands for CD80 and CD86 (Salomon and Bluestone, 2001; Tang and Bluestone, 2008) . A previous study revealed that CD80 expressed on DCs acts preferentially as a ligand for CTLA-4 and mediates Treg cell suppression . However, whether this exact mechanism is utilized by Breg cells will be subject for future investigations. Defects in regulatory T cells have been identified in several autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), and SLE (Ehrenstein et al., 2004; Viglietta et al., 2004) . Here, we propose that regulatory B cells may also be defective in SLE patients. Because of the profound lymphopenia that characterizes the majority of patients with SLE, and the small volumes of SLE PB available from active patients, we have not been able to directly test the suppressive capacity of purified CD19 + CD24 B cells in patients with SLE display a variety of abnormalities including abnormal expression or function of key signaling molecules, costimulatory pathways, cytokines, and perturbations in developmental subsets (Grammer and Lipsky, 2003 (Koshy et al., 1996) . It is conceivable that this change might result in the overstimulation of SLE Breg cells, perhaps rendering them less capable of an appropriate IL-10 response upon CD40 engagement, followed by PMA+iono stimulation, in a context where they would otherwise have a regulatory function. Our results also shed further light on previous data showing that the strength of CD40 stimulation may dictate the direction (activation versus inhibition) of B cell responses (Mathur et al., 2004; Miyashita et al., 1997) . Our combined studies provide important new data defining the phenotype and suppressive activity for a potential regulatory B cell population in healthy humans and for a defect in the activity of such cells in an autoimmune disease setting. At present, our data are insufficient to determine whether the defective response to CD40 stimulation in CD19 + CD24
hi CD38 hi SLE B cells and the failed suppressive capacity of this population reflects an initiating, as opposed to a secondary, effect of SLE disease processes. Ongoing studies designed to test whether regulatory B cell function can be restored after B cell depletion therapy in SLE may help to address this question. In association with previous reports showing defects in Treg cell activity in SLE, our data suggests that a broad range of deficiencies in immune regulatory cell function may be present in this and, possibly, other autoimmune diseases.
EXPERIMENTAL PROCEDURES
Patients and Controls SLE patients fulfilling the American College of Rheumatology revised classification criteria for lupus (Tan et al., 1982) were assessed for disease activity with the British Isles Lupus Assessment Group index (Hay et al., 1993) . Only patients with active SLE (British Isles Lupus Assessment global score higher than 4) were included (mean age, 39 years; age range, 19-76 years). Table 1 summarizes the characteristics of patients with SLE. Healthy individuals (mean age, 38 years; age range, 24-64 years) were studied in parallel as controls. Age-matched patients with Sjö gren's syndrome disease and patients with osteoarthritis (mean age 65) were included in this study as disease control (OAD). The ethics committee of the University College London Hospitals National Health Service Trust approved this study; patients and healthy volunteers were recruited after obtaining informed consent. lated STAT-3 phosphorylation by SLE and healthy B cell subsets. B cell subset kinase activity in response to CD40 ligation was assessed by measurement of STAT-3 phosphorylation by flow cytometry after stimulating PBMC from healthy controls (n = 6) and SLE patients (n = 6) in vitro with agonistic CD40 mAb (0.5 mg/10 6 cells). Cells were surface stained with CD19, CD24, and CD38 mAbs.
Human Cell Isolation
(E) STAT-3 phosphorylation at 5 min post stimulation with CD40 mAb is depicted. Phosphorylation is plotted as mean percentage increase ± SE in pSTAT-3 compared to the unstimulated control at time zero. Difference between pairs was evaluated by two-way ANOVA; * p <0. 
Cytokine Detection
For analysis of human intracellular cytokine production, PBMCs were stimulated with either 0.5 mg/ml purified plate-bound CD3 mAb (Hit-3a) (BD Biosciences) for 3 days for T cell cocultures, or with CD154 expressing CHO cells (1:10 CHO:B cells or PBMCs) or 0.1 mg/ml CpG ODN2006 (Invivogen, San Diego, USA) for 72 hr for B cells. GolgiPlug (BD Biosciences) was added for the last 6 hr along with PMA+iono. For intracellular staining, cells were stained with combinations of CD4-Alexa Fluor488, CD19-PE-Cy7, CD38-FITC, CD38-PE-Cy5, CD24-PE, CD24-biotin, and CD24-FITC mAbs (BD Biosciences). Cells were washed, fixed, permeabilized, and stained for detection of intracellular cytokines with IFN-g-APC, TNFa-APC, and IL-10-APC mAbs (BD Biosciences). Appropriate APC-conjugated isotype controls were used for gate setting for cytokine expression. Alternatively, IL-10 was measured in the culture supernatants by ELISA (BD Biosciences) with aliquots of supernatant taken from cell cultures before the addition of GolgiPlug and PMA+iono to the cultures.
Cell Signaling
PBMCs were rested for 1 hr in medium. Cells were then stimulated by incubation with 5 mg/ml purified stimulatory mouse-anti-human CD40 mAb (clone-5C3, BD Biosciences) (0.5 mg CD40 mAb/10 6 cells) for 30 min on ice in the dark. Cells were washed with ice-cold PBS, 5 mg/ml goat anti-mouse IgG F(ab') 2 was added, and finally the cells were incubated at 4 C for 20 min. Cells were stained with appropriate antibodies for 30 min in ice-cold PBS at 4C. Cells were washed with ice-cold PBS, resuspended in warm PBS, and The following abbreviations are used: arthritis (a), serositis (ser), skin vasculitis (sv), lymphadenopathy (lym), skin rash (sr), hemolytic (h), anemia (an), nephritis (n), fever (f), organic brain syndrome (obs), autoimmune thrombocytopaenia (at), predinsolone (pred), hydroxychloroquine (hcq), methotrexate (mtx), azathioprine (aza), mycophenolate (mmf), and not treated (nt).
incubated for up to 30 min at 37 C and fixed. Phosphorylated Stat3-PE mAb Phosflow antibody (BD Biosciences) was used at a 1:50 dilution of stock in Permwash (BD Biosciences) with 50 ml/well.
B Cell Functional Assays
Cocultures of 2.5 3 10 5 B cells and 2.5 3 10 5 CD4 + CD25 À T cells (1:1) were stimulated with plate-bound CD3 mAb (0.5 mg/ml) for 72 hr. GolgiPlug (BD Biosciences) was added for the last 6 hr along with PMA+iono. Cells were surfaced stained, permeabilized, stained intracellularly for IFN-g and TNF-a, and analyzed by flow cytometry. For experiments with purified SLE CD4 + T cells, autologous irradiated PBMCs (40 Gy dose), depleted of CD4 + T cells by magnetic-bead purification, were also added at a ratio of 1:10 irradiated PBMCs:CD4 + T cells.
Statistics
All values are expressed as mean ± SEM. We performed analysis of significance in Prism (GraphPad, La Jolla, USA) by the two-tailed t test analysis and by two-way ANOVA.
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